Rein Therapeutics, Inc. Segments Disclosure
13. Segment Reporting
The Company has one reportable segment which focuses on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. The Company’s CODM, the , manages the Company’s operations on a consolidated basis as one operating segment for the purposes of evaluating financial performance and allocating resources.
The Company has not generated any revenue yet. The CODM assesses the financial performance of the segment and decides how to allocate resources based on net loss on a consolidated basis. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.
The CODM uses net loss predominantly in the annual operating budget and in the strategic planning and forecasting process. Such loss measure is used to monitor budget versus actual results on an ongoing basis by the CODM and determine how resources are allocated to the various activities of the Company. The CODM also uses net loss to evaluate the Company’s performance and assist in determination of management’s incentive compensation.
All of the Company’s tangible assets are held in the United States. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
The table below is a summary of the segment loss, including significant segment expenses:
|
|
Year Ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Revenues |
|
$ |
— |
|
|
$ |
— |
|
Research and development expenses: |
|
|
|
|
|
|
||
LTI-01 program-related expenses: |
|
|
|
|
|
|
||
Preclinical study costs |
|
|
— |
|
|
|
2 |
|
CMC activities |
|
|
1,066 |
|
|
|
3,566 |
|
Clinical operation activities |
|
|
413 |
|
|
|
46 |
|
Total LTI-01 program-related expenses |
|
|
1,479 |
|
|
|
3,614 |
|
LTI-03 program-related expenses: |
|
|
|
|
|
|
||
Preclinical study costs |
|
|
778 |
|
|
|
1,935 |
|
CMC activities |
|
|
2,239 |
|
|
|
2,451 |
|
Clinical operation activities |
|
|
4,285 |
|
|
|
3,913 |
|
Total LTI-03 program-related expenses |
|
|
7,302 |
|
|
|
8,299 |
|
Other program-related expenses |
|
|
11 |
|
|
|
54 |
|
Employee related expenses |
|
|
2,119 |
|
|
|
2,200 |
|
Professional fees for services |
|
|
44 |
|
|
|
34 |
|
Facilities and other expenses |
|
|
74 |
|
|
|
47 |
|
Total research and development expenses |
|
|
11,029 |
|
|
|
14,248 |
|
General and administrative expenses: |
|
|
|
|
|
|
||
Employee related expenses |
|
|
3,748 |
|
|
|
5,465 |
|
Professional fees for services |
|
|
5,191 |
|
|
|
6,257 |
|
Facilities and other expenses |
|
|
1,963 |
|
|
|
2,142 |
|
Total general and administrative expenses |
|
|
10,902 |
|
|
|
13,864 |
|
Impairment loss on intangible assets |
|
|
28,700 |
|
|
|
37,000 |
|
Other income, net |
|
|
(48 |
) |
|
|
(685 |
) |
Income tax benefit |
|
|
(712 |
) |
|
|
(1,544 |
) |
Segment and consolidated net loss |
|
$ |
(49,871 |
) |
|
$ |
(62,883 |
) |
Want the next Rein Therapeutics, Inc. segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Rein Therapeutics, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 26, 2026 | Showing above |
| 2024 | Apr 7, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.